236 related articles for article (PubMed ID: 23419507)
21. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma.
Tseng JS; Yang TY; Tsai CR; Chen KC; Hsu KH; Tsai MH; Yu SL; Su KY; Chen JJ; Chang GC
J Thorac Oncol; 2015 Apr; 10(4):603-10. PubMed ID: 25514801
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics, tumor, node, metastasis status, and mutation rate in domain of epidermal growth factor receptor gene in serbian patients with lung adenocarcinoma.
Zaric B; Stojsic V; Kovacevic T; Sarcev T; Tepavac A; Jankovic R; Spasic J; Radosavljevic D; Zarogoulidis P; Vukobradovic-Djoric N; Perin B
J Thorac Oncol; 2014 Sep; 9(9):1406-10. PubMed ID: 25122436
[TBL] [Abstract][Full Text] [Related]
23. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
[No Abstract] [Full Text] [Related]
24. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive?
Usuda K; Sagawa M; Motono N; Ueno M; Tanaka M; Machida Y; Matoba M; Taniguchi M; Tonami H; Ueda Y; Sakuma T
Asian Pac J Cancer Prev; 2014; 15(2):657-62. PubMed ID: 24568474
[TBL] [Abstract][Full Text] [Related]
25. CT Features of Epidermal Growth Factor Receptor-Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma.
Hasegawa M; Sakai F; Ishikawa R; Kimura F; Ishida H; Kobayashi K
J Thorac Oncol; 2016 Jun; 11(6):819-26. PubMed ID: 26917231
[TBL] [Abstract][Full Text] [Related]
26. [Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma].
Zhang H; Yang X; Qin N; Li X; Yang H; Nong J; Lv J; Wu Y; Zhang Q; Zhang X; Wang J; Zhou L; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Nov; 18(11):686-90. PubMed ID: 26582224
[TBL] [Abstract][Full Text] [Related]
27. Identification of epidermal growth factor receptor mutations in pulmonary adenocarcinoma using dual-energy spectral computed tomography.
Li M; Zhang L; Tang W; Jin YJ; Qi LL; Wu N
Eur Radiol; 2019 Jun; 29(6):2989-2997. PubMed ID: 30367185
[TBL] [Abstract][Full Text] [Related]
28. The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma.
Deng H; Liu J; Duan X; Liu Y
Pathol Res Pract; 2018 Mar; 214(3):450-454. PubMed ID: 29496311
[TBL] [Abstract][Full Text] [Related]
29. Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma.
Shi Z; Zheng X; Shi R; Song C; Yang R; Zhang Q; Wang X; Lu J; Yu Y; Liu Q; Jiang T
Sci Rep; 2017 Mar; 7(1):364. PubMed ID: 28336963
[TBL] [Abstract][Full Text] [Related]
30. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
31. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Jain A; Lim C; Gan EM; Ng DZ; Ng QS; Ang MK; Takano A; Chan KS; Tan WM; Kanesvaran R; Toh CK; Loo CM; Hsu AA; Devanand A; Lim CH; Koong HN; Koh T; Fong KW; Yap SP; Kim SW; Chowbay B; Oon L; Lim KH; Lim WT; Tan EH; Tan DS
PLoS One; 2015; 10(5):e0123587. PubMed ID: 25955322
[TBL] [Abstract][Full Text] [Related]
32. Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.
Erdogan B; Kodaz H; Karabulut S; Cinkaya A; Tozkir H; Tanriverdi O; Cabuk D; Hacioglu MB; Turkmen E; Hacibekiroglu I; Uzunoglu S; Cicin I
Bosn J Basic Med Sci; 2016 Nov; 16(4):280-285. PubMed ID: 27371767
[TBL] [Abstract][Full Text] [Related]
33. Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma.
Chen Y; Yang Y; Ma L; Zhu H; Feng T; Jiang S; Wei Y; Wang T; Sun X
Eur J Radiol; 2019 Mar; 112():44-51. PubMed ID: 30777218
[TBL] [Abstract][Full Text] [Related]
34. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
[TBL] [Abstract][Full Text] [Related]
35. Analysis of CT features and quantitative texture analysis in patients with lung adenocarcinoma: a correlation with EGFR mutations and survival rates.
Sacconi B; Anzidei M; Leonardi A; Boni F; Saba L; Scipione R; Anile M; Rengo M; Longo F; Bezzi M; Venuta F; Napoli A; Laghi A; Catalano C
Clin Radiol; 2017 Jun; 72(6):443-450. PubMed ID: 28258739
[TBL] [Abstract][Full Text] [Related]
36. Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study.
Min KW; Kim WS; Jang SJ; Choi YD; Chang S; Jung SH; Kim L; Roh MS; Lee CS; Shim JW; Kim MJ; Lee GK;
QJM; 2016 Mar; 109(3):167-73. PubMed ID: 26031706
[TBL] [Abstract][Full Text] [Related]
37. CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses.
Mei D; Luo Y; Wang Y; Gong J
Cancer Imaging; 2018 Dec; 18(1):52. PubMed ID: 30547844
[TBL] [Abstract][Full Text] [Related]
38. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
Liam CK; Ruthranesan M; Lee CH; Pang YK; Chua KT; Lim BK
Asia Pac J Clin Oncol; 2012 Sep; 8(3):267-74. PubMed ID: 22897510
[TBL] [Abstract][Full Text] [Related]
40. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]